Regulation of inside-out β1-integrin activation by CDCP1

Area of Science:

• Oncology
• Cell Biology
• Molecular Biology

Background:

• Tumor metastasis is regulated by cell adhesion molecules like β1-integrin.
• Cub-Domain Containing Protein-1 (CDCP1) is a transmembrane glycoprotein involved in cell adhesion.
• Altered CDCP1 expression is linked to metastatic progression in various cancers.

Purpose of the Study:

• Investigate the role of CDCP1 in castrate-resistant prostate cancer (CRPC) progression.
• Elucidate the mechanism by which CDCP1 loss affects cell adhesion, proliferation, and tumor growth.
• Identify the molecular pathway linking CDCP1 to β1-integrin activation and CDK5 activity.

Main Methods:

• Reduced CDCP1 expression was analyzed in patient samples (primary tumors, CTCs, metastases).
• CDCP1 function was assessed in prostate cancer cell lines (DU145, PC3) using silencing techniques.
• Tumor growth was evaluated in mouse models.
• Molecular mechanisms involving CDK5, c-SRC, PKCδ, and β1-integrin were investigated through phosphorylation site analysis.

Main Results:

• CDCP1 expression is reduced in high-grade CRPC, circulating tumor cells, and metastases.
• CDCP1 silencing increased non-adherent cell proliferation, anchorage-independent growth, and tumor formation in mice.
• Loss of CDCP1 diminished cell adhesion and migration by impairing β1-integrin activation.
• CDCP1 loss reduces CDK5 activity via c-SRC and PKCδ-mediated phosphorylation of CDK5R1/p35 and CDK5.

Conclusions:

• Reduced CDCP1 expression is associated with aggressive prostate cancer and promotes metastasis.
• CDCP1 loss dysregulates CDK5 activity, leading to impaired β1-integrin activation and enhanced non-adherent cell behavior.
• This pathway represents a novel mechanism contributing to prostate cancer vascular dissemination.